PPAR-gamma Signaling in Metabolic Homeostasis

Rina Triana, Nurrani Mustika Dewi, Siska Darmayanti, Eka Herawati, Maria Novalentina, Made Putra Semadhi, Miftakh Nur Rahman

Abstract


BACKGROUND: Peroxisome proliferator-activated receptor (PPAR)-γ, or also known as nuclear receptor subfamily 1 group C member 3 (NR1C3), is a PPAR which serves as master regulator of adipocytes differentiation, and plays an important role in lipid metabolism or adipogenesis. Recent study showed that PPAR-γ is expressed in most tissue and also has critical impact in many metabolic homeostasis disorders.

CONTENT: Dysregulation of PPAR-γ is correlated to the development of obesity, type 2 diabetes, atherosclerosis, cardiovascular disease, acute kidney injury, autoimmune disease, gastrointestinal disease and Alzheimer’s disease. Abundant number of new emerging compounds, with in vitro and in vivo effectiveness as natural and synthetic agonists of PPARs, are investigated, developed and used as the treatment of metabolic disorders of glucose and/or lipid and other diseases.

SUMMARY: Based on all studies explanation, targeting PPAR-γ is proven to be a good therapeutic method for reducing negative effect of several metabolic homeostasis disorder. Now, many natural and synthetic agonists of PPARs are used as the treatment of metabolic disorders of glucose and/or lipid or another metabolic homeostasis disorder. Such agonists have different properties and specificities for individual PPARs receptors, different absorption and distribution, and distinctive gene expression profiles, which ultimately lead to different clinical outcomes.

KEYWORDS: PPAR-γ, dysregulation, agonist, adipogenesis, metabolic disorder, homeostasis


Full Text:

PDF

References


Ahmadian M, Suh J, Hah N, Liddle C, Atkins A, Downes M, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013; 99: 557-66, CrossRef.

Janani C, Ranjitha KB. PPAR gamma gene -- a review. Diabetes Metab Syndr. 2015; 9: 46-50, CrossRef.

Lehrke M, Lazar M. The many faces of PPARγ. Cell. 2005; 123: 993-9, CrossRef.

SABiosciences [Internet]. PPAR Pathway [cited April 20, 2016]. Available from:

hp?sn=PPAR_Pathway">http://www.sabiosciences.coms/.

Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPARgamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001; 7: 48-52, CrossRef.

Kelly DP. The pleiotropic nature of the vascular PPAR gene regulatory pathway. Circ Res. 2001; 89: 935-7, PMID.

Nuclear Receptor Resource [Internet]. PPARgamma Pathway [cited April 20, 2016]. Available from:

ppargamma_pathway.html">http://nrresource.org/.

Hata K, Nishimura R, Ikeda F, Yamashita K, Matsubara T, Nokubi T et al. Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis. Mol Biol Cell. 2003; 14: 545-55, CrossRef.

Zhang J, Fu M, Zhu X, Xiao Y, Mou Y, Zheng H, et al. Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem. 2002; 277: 11505-12, CrossRef.

Ortuño Sahagún D, Márquez-Aguirre AL, Quintero-Fabián S, López-Roa RI, Rojas-Mayorquín AE. Modulation of PPAR gamma by nutraceutics of complementary treatment for obesuty related disorders and inflammatory diseases. PPAR Res. 2012; 2012: 318613, CrossRef.

González JPM, Borrella CC, Mayoral R, Gudino LC, Hoghtower CM, Sarmiento RG. PPAR gamma pro12Ala polymorphism and type 2 diabetes: a study in a spanish cohort. J Genet Stud. 2014; 2: 1, CrossRef.

Berger J. Role of PPARγ, transcriptional cofactors, and adiponectin in the regulation of nutrient metabolism, adipogenesis and insulin action: view from the chair. Int J Obes Relat Metab Disord. 2005; 29: S3-4, CrossRef.

Choi S, Kim E, Jung J, Marciano D, Jo A, Koo J, et al. PPARγ antagonist gleevec improves insulin sensitivity and promotes the browning of white adipose tissue. Diabetes. 2016; 65: 829-39, CrossRef.

Akyurek N, Aycan Z, Cetinkaya S, Akyurek O, Yilmaz Agladioglu S, Ertan U. Peroxisome proliferator activated receptor (PPAR)-gamma concentrations in childhood obesity. Scand J Clin Lab Invest. 2013; 73: 355-60, CrossRef.

Farmer S. Regulation of PPARγ activity during adipogenesis. Int J Obes Relat Metab Disord. 2005; 29: S13-6, CrossRef.

Larsen T, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with longterm efficacy?. Int J Obes Relat Metab Disord. 2003; 27: 147-61, CrossRef.

Das SK, Chakrabarti R. Role of PPAR in cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 2006; 1: 193-209, CrossRef.

Meiliana A, Wijaya A. Novel Biomarkers in Cardiovascular Disease: A Review. Indones Biomed J. 2010; 2: 66-91, CrossRef.

Huang JV, Greyson CR, Schwartz GG. PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res. 2012; 53: 1738-54, CrossRef.

Calkin AC, Thomas MC. PPAR Agonists and Cardiovascular Disease in Diabetes.PPAR Res. 2008; 2008: 1-12, CrossRef.

Finck B. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res. 2007; 73: 269-77, CrossRef.

Duan SZ, Ivashchenko CY, Usher MG, Mortensen RM. PPAR-γ in the cardiovascular system. PPAR Res. 2008; 2008: 745804, CrossRef.

Rojas J, Salazar J, Martínez MS, Palmar J, Bautista J, Chávez-Castillo M, et al. Macrophage heterogeneity and plasticity: impact of macrophage biomarkers on atherosclerosis. Scientifica. 2015; 2015: 851252, CrossRef.

Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol. 2011; 300: H1566-82, CrossRef.

Ding X, Wang R, Liu L, Yu Q, Wang Z, Ma Z, et al. Interaction between peroxisome proliferator-activated receptor gamma and smoking on cardiovascular disease. Physiol Behav. 2016; 153: 28-32, CrossRef.

Kapil A, Singh J, Kaur T, Singh B, Singh A. Involvement of peroxisome proliferator–activated receptor gamma in vitamin D-mediated protection against acute kidney injury in rats. J Surg Res. 2013; 185: 774-83, CrossRef.

Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Compr Physiol. 2012; 2: 1303-53, CrossRef.

de Bragança AC, Volpini RA, Canale D, Gonçalves JG, Shimizu MHM, Sanches TR, et al. Vitamin D deficiency aggravates ischemic acute kidney injury in rats. Physiol Rep. 2015; 3: e12331, CrossRef.

Cheng CF, Chen HH, Lin H. Role of PPAR-α and its agonist in renal diseases. PPAR Res. 2010; 2010: 345098, CrossRef.

Choi J, Bothwell A. The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells. 2012; 33: 217-22, CrossRef.

Kasai K, Banba N, Hishinuma A, Matsuura M, Kakishita H, Matsumura M, et al. 15-Deoxy-Δ12,14-prostaglandin J2 facilitates thyroglobulin production by cultured human thyrocytes. Am J Physiol Cell Physiol. 2000; 279: C1859-69, PMID.

Mimura L, Villares S, Monteiro M, Guazzelli I, Bloise W. Peroxisome proliferator-activated receptor-γ gene expression in orbital adipose/connective tissues is increased during the active stage of graves' ophthalmopathy. Thyroid. 2003; 13: 845-50, CrossRef.

Ferrari S, Fallahi P, Vita R, Antonelli A, Benvenga S. Peroxisome proliferator-activated receptor-γ in thyroid autoimmunity. PPAR

Res. 2015; 2015: 1-8, CrossRef.

Martin H. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. Mutat Res. 2010; 690: 57-63, CrossRef.

Annese V, Rogai F, Settesoldi A, Bagnoli S. PPARγ in inflammatory bowel disease. PPAR Res. 2012; 2012: 1-9, CrossRef.

Necela B, Thompson E. Pathophysiological roles of PPARγ in gastrointestinal epithelial cells. PPAR Research. 2008; 2008: 1-8, CrossRef.

Sartor R. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 390-407, CrossRef.

Kummer MP, Heneka MT. PPARs in Alzheimer’s disease. PPAR Res. 2008; 2008: 1-8, CrossRef.

Jiang Q, Heneka MT, Landreth GE. The role of peroxisome proliferator-activated receptor-γ PPARγ in Alzheimer’s disease. CNS Drugs. 2008; 22: 1-14, CrossRef.

Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer’s disease: inhibition of β amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR-γ agonists. J Neurosci. 2000; 20: 558-67, PMID.

Heneka MT, Reyes-Irisarri E, Hüll M, Kummer MP. Impact and therapeutic potential of PPARs in alzheimers disease. Curr Neuropharmacol. 2011; 9: 643-50, CrossRef.

Lee JE, Ge K. Transcriptional and epigenetic regulation of PPARγ expression during adipogenesis. Cell Biosci. 2014; 4: 29, CrossRef.

Monajemi H, Zhang L, Li G, Jeninga EH, Cao H, Maas M, et al. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptorgamma. J Clin Endocrinol Metab. 2007; 92: 1606-12, CrossRef.

Wu Z, Bucher NL, Farmer SR. Induction of peroxisome proliferatoractivated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol. 1996; 16: 4128-36, CrossRef.

Tong Q, Tsai J, Tan G, Dalgin G, Hotamisligil GS. Interaction between GATA and the C/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation. Mol Cell Biol. 2005; 25: 706-15, CrossRef.

Wang L, Waltenberger B, Pferschy-Wenzig E-M, Blunder M, Liu X, Malainer C, et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARg): a review. Biochem Pharmacol. 2014; 91: 73-89, CrossRef.

Szeles L, Torocsik D, Nagy L. PPARgamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta. 2007; 1771: 1014-30, CrossRef.

Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review. Nutr J. 2014; 13: 17, CrossRef.

Heikkinen S, Auwerx J, Argmann CA. PPARγ in human and mouse physiology. Biochim Biophys Acta. 2007; 1771: 999-1013, CrossRef.

Margeli A, Kouraklis G, Theocharis S. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis. 2003; 6: 165-9, CrossRef.

Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005; 67: 15-9, CrossRef.

Caballero A, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O’Connor C, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003; 52: 173-80, CrossRef.

Weidner C, de Groot JC, Prasad A, Freiwald A, Quedenau C, Kliem M, et al. Amorfrutins are potent antidiabetic dietary natural products. Proc Natl Acad Sci USA. 2012; 109: 7257-62, CrossRef.

Doshi LS, Brahma MK, Bahirat UA, Dixit AV, Nemmani KV. Discovery and development of selective PPARg modulators as safe and effective antidiabetic agents. Expert Opin Investig Drugs. 2010; 19: 489-512, CrossRef.




DOI: https://doi.org/10.18585/inabj.v8i3.209

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute